Search review questions

Withdrawals due to adverse events · acute gout

Total adverse events · acute gout

Pain: mean change from baseline on 5‐point (0 to 4, 0 no pain) Likert scale · acute gout

Inflammation (swelling): mean change from baselineon 4‐point (0 to 3, 0 no swelling) Likert scale · acute gout

Acute gout flaresParticipant self‐report, using gout flare diary · people with chronic gout

sUA reduction · peoeple with chronic gout and sUA level > 0.36 mmol/L

Joint pain reduction · peoeple with chronic gout and sUA level > 0.36 mmol/L

Participant global assessment · peoeple with chronic gout and sUA level > 0.36 mmol/L

Total adverse events · peoeple with chronic gout and sUA level > 0.36 mmol/L

Tophus regression · peoeple with chronic gout and sUA level > 0.36 mmol/L

Study withdrawals due to adverse events · people with chronic gout

sUA acid reductionb (in mmol/L) · people with chronic gout

Joint pain reduction10‐point Likert scale (0 = no pain) · people with chronic gout

Participant global assessment 5‐point Likert scale (5 = excellent) · people with chronic gout

Total adverse eventsd · people with chronic gout

Tophus regression · people with chronic gout

Acute gout flares · peoeple with chronic gout and sUA level > 0.36 mmol/L

Study withdrawals due to adverse events · peoeple with chronic gout and sUA level > 0.36 mmol/L

Reduction of at least 4 points in SELENA‐SLEDAI at 52 weeks SELENA‐SLEDAI score, a validated marker of SLE disease activity (range 0 to 105; higher score = worse disease activity) · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Change in HRQOL, on SF‐36 PCS score at 52 weeks Improvement in SF‐36 PCS score from baseline ( · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Reduction of glucocorticoid dose by at least 50% · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Participants with one or more serious adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Participants with one or more serious infections · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Withdrawals due to adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Number of participants who died during the study · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Pain (VAS, PRTEE) translated to 0 to 10, where 0 is no pain · lateral elbow pain

Function (PRTEE, DASH, MMCPIE, Roles‐Maudsley), translated to 0 to 100, where 0 is best function, or no disability · lateral elbow pain

Treatment success (> 25% improvement in pain or function) · lateral elbow pain

Health‐related quality of life Not measured · lateral elbow pain

Pain relief ≥ 30% or ≥ 50% Not measured at 3 months · lateral elbow pain

Withdrawal due to adverse events  · lateral elbow pain

Adverse events (pain and swelling at injection site and limitation of elbow movement following injection) · lateral elbow pain

Overall pain · rotator cuff disease

Pain on motion · rotator cuff disease

Active range of motion (shoulder abduction) without pain. Scale: 0 to 180 degrees№ of participants: 143(3 RCTs) · rotator cuff disease

Quality of life · rotator cuff disease

Global assessment of treatment success№ of participants: (0 studies) · rotator cuff disease

Adverse events№ of participants: 391 (7 RCTs) · rotator cuff disease

Function · rotator cuff disease

Pain on motion · rotator cuff disease

Active range of motion (shoulder abduction) without pain. Scale: 0 to 180 degrees№ of participants: 68(2 RCTs) · rotator cuff disease

Global assessment of treatment success№ of participants: (0 studies) · rotator cuff disease

Quality of life№ of participants: (0 studies) · rotator cuff disease

Adverse events№ of participants: 136 (4 RCTs) · rotator cuff disease

Overall pain · rotator cuff disease

Function · rotator cuff disease

Resolution at 12 to 24 weeks Quinell Grade (range 0 to 4, resolved disease is grade 0) · adults (> 18 years of age) with trigger finger

Persistent moderate to severe symptoms at 12 to 24 weeks · adults (> 18 years of age) with trigger finger

Recurrence at 12 to 24 weeks · adults (> 18 years of age) with trigger finger

Total active motion · adults (> 18 years of age) with trigger finger